Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.

Antidepressant use after colon cancer diagnosis does not increase risk of recurrence

17 Feb 2019

Though the use of antidepressants after diagnosis is widespread among colon cancer patients, it does not appear to increase the risk of recurrence, reports a new study.

Of the 1,923 adult colon cancer patients (aged 18 years; 52.4 percent male) included in the study, 807 reported any antidepressant use after being diagnosed. The resulting prevalence rate was 42 percent. Only those with stage I–IIIA malignant adenocarcinoma of the colon or of the rectosigmoid junction were eligible for inclusion.

Over a median follow-up of 4.7 years (10,831 person-years), 139 participants had cancer recurrence, yielding a recurrence rate of 12.8 per 1,000 person-years. There was no significant difference in the risk of recurrence between those who did and did not use antidepressants after diagnosis (hazard ratio [HR], 1.14; 95 percent CI, 0.69–1.87).

Analysis according to type of antidepressant used produced similar results. The use of neither selective serotonin reuptake inhibitors (SSRI; HR, 1.22; 0.64–2.30) nor tricyclic antidepressants (TCA; HR, 1.18; 0.68–2.07) significantly increased the likelihood of colon cancer recurrence.

In a secondary analysis, antidepressant use also did not significantly increase the risk of developing a second primary colorectal cancer (HR, 1.32; 0.86–2.02; SSRIs: HR, 1.16; 0.68–1.99; TCA: HR, 1.24; 0.77–2.00).

The findings were robust to various sensitivity analyses, wherein the definition of colorectal cancer was expanded or the sample was restricted to those with at least two antidepressant prescriptions or those without prediagnosis medication use.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
12 Jun 2020
Drawing from experience as a key investigator in landmark clinical trials (including PALOMA, MONALEESA and MONARCH), and his clinical experience with CDK4/6 inhibitors, Dr Rafael Villanueva Vázquez shares his insights into the current evidence of using CDK4/6 inhibitors to treat HR+/HER2- ABC.